LysinBio

LysinBio is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation antimicrobial agents known as lysins or enzybiotics. The company's proprietary platform focuses on engineering bacteriophage-derived enzymes that rapidly and specifically degrade the peptidoglycan layer of bacterial cell walls, providing a potent alternative to traditional antibiotics. LysinBio's lead candidate, LSB-101, is currently being evaluated in clinical trials for the treatment of serious infections caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA). Beyond its lead program, the company is advancing a pipeline of lysin-based therapies targeting other high-priority Gram-negative pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa. By addressing the critical global challenge of multi-drug resistant bacterial infections, LysinBio aims to provide life-saving treatments for patients with limited therapeutic options.